Evaluation of KITE-222 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The primary objective of this study is to evaluate the efficacy and safety of **KITE-222** in participants with relapsed or refractory **Acute Myeloid Leukemia** (AML). This is clinically relevant as AML is a rapidly progressing hematologic malignancy with limited treatment options for patients who do not respond to initial therapy or experience a relapse. Understanding the potential benefits and risks associated with KITE-222 could provide critical insights into new therapeutic avenues for this patient population.

The clinical trial involves a study population diagnosed with **Acute Myeloid Leukemia**. The trial includes both male and female participants, with an age range encompassing both adults and adolescents. The total number of participants is one. The trial population was selected to include a vulnerable population, although specific lifestyle considerations such as diet, physical activity, or habits are not detailed. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of a novel therapeutic intervention in participants with **Acute Myeloid Leukemia** who have experienced relapse or are refractory to standard treatments. This study is structured as a Phase 1 trial, which is typically focused on assessing the safety profile and determining the appropriate dosage of the investigational product. The trial is expected to commence recruitment on October 16, 2023, and is projected to conclude by July 30, 2026. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results, minimizing bias and allowing for a robust comparison between the investigational product and a control.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following successful screening, participants will be randomized and begin the treatment phase. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the treatment's effects, and collect data on any adverse events. These visits are integral to maintaining participant safety and gathering comprehensive data on the investigational product's performance.

The end-of-study visit marks the conclusion of a participant's involvement in the trial. During this visit, final assessments are conducted to evaluate the overall impact of the treatment. The expected length of participant involvement varies depending on individual response and the study's progression but generally aligns with the trial's overall duration. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. Such conditions are in place to prioritize participant safety and maintain the integrity of the trial data.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is October 16, 2023, with an anticipated completion by July 30, 2026. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the intervention's effect on the disease. The trial will likely employ standardized methods for measuring and analyzing efficacy, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the nature of the intervention and the disease being studied. The schedule for these assessments is typically aligned with the trial's timeline, ensuring data collection at relevant timepoints throughout the study duration. The use of specific tools or instruments for efficacy assessments is not specified, but they are generally selected based on their relevance and reliability in capturing the desired outcomes.